Malignant solid tumors
Conditions
Interventions
Sponsors
The 2nd Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 75; 2. Patients confirmed as having solid tumors by imaging examinations or pathology; 3. Informed consent must be signed in person by the subject or their legal guardian or caregiver, who is willing and capable of cooperating with all projects of this study.
Exclusion criteria
Exclusion criteria: 1. Suffering from serious other neurological diseases, or gastrointestinal, cardiovascular, liver, kidney, blood system, respiratory system, immune deficiency and other serious diseases; 2. The candidate subjects have contraindications for PET/CT scans, including but not limited to uncontrolled elevated blood sugar; pregnant women, lactating women; those who cannot accept repeated intravenous injections; claustrophobia; 3. Those who are known to be allergic to humanized monoclonal antibody products; 4. In the past year, apart from the radiation exposure expected in this clinical study, the subject has participated in other research programs or clinical care, resulting in radiation exposure exceeding an effective dose of 50 mSv; 5. The candidate subjects have received experimental drug or device treatment (with unclear efficacy or safety) within one month; 6. The candidate subjects have any clinical conditions that the leader of this study believes may cause or potentially be harmful to this preparation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SUVmax, Standardized Uptake Value Maximum;Specificity;Sensitivity;TBR, target background ratio;Adverse reactions; | — |
Countries
China
Contacts
Public ContactLiang Cai
The 2nd Affiliated Hospital of Chongqing Medical University
Outcome results
None listed